AllPennyStocks.com AZN Stock Slips After-Hours Following Latest Late-Stage Oncology Trial Miss — Executive ‘Disappointed,’ Reiterates Breast Cancer Focus
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

AZN Stock Slips After-Hours Following Latest Late-Stage Oncology Trial Miss — Executive ‘Disappointed,’ Reiterates Breast Cancer Focus

A combination of the company’s breast cancer drug Etcamah did not delay worsening of the disease enough to meet the SERENA-4 late-stage trial’s main goal, AstraZeneca said.

Other Penny Stock Movers

This Critical Minerals Explorer Just Found Where to Look Next
This Cannabis Microcap Just Bought Its Way Into Two of Europe's Biggest Markets
BC Copper-Gold Explorer Surges 40% on Maiden Drill Visuals
Most Popular
{{ index + 1 }}


Back to Top